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Abstract
Recent reports suggest that a growing number of human immunodeficiency virus (HIV)-infected 
persons show signs of persistent cognitive impairment even in the context of combination 
antiretroviral therapies (cART). The basis for this finding remains poorly understood as there are 
only a limited number of studies examining the relationship between CNS injury, measures of 
disease severity, and cognitive function in the setting of stable disease. This study examined the 
effects of HIV infection on cerebral white matter using quantitative morphometry of the 
midsagittal corpus callosum (CC) in 216 chronically infected participants from the multisite HIV 
Neuroimaging Consortium study currently receiving cART and 139 controls. All participants 
underwent MRI assessment, and HIV-infected subjects also underwent measures of cognitive 
function and disease severity. The midsagittal slice of the CC was quantified using two semi-
automated procedures. Group comparisons were accomplished using ANOVA, and the 
relationship between CC morphometry and clinical covariates (current CD4, nadir CD4, plasma 
and CSF HIV RNA, duration of HIV infection, age, and ADC stage) was assessed using linear 
regression models. HIV-infected patients showed significant reductions in both the area and linear 
widths for several regions of the CC. Significant relationships were found with ADC stage and 
nadir CD4 cell count, but no other clinical variables. Despite effective treatment, significant and 
possibly irreversible structural loss of the white matter persists in the setting of chronic HIV 
disease. A history of advanced immune suppression is a strong predictor of this complication and 
suggests that antiretroviral intervention at earlier stages of infection may be warranted.
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Introduction
Prior to the advent of combination antiretroviral therapies (cART), both neurocognitive 
impairment (i.e., dementia (Antinori et al. 2007; Levy and Bredesen 1988; Navia et al. 1986; 
Navia and Price 1987)) and structural neuroimaging abnormalities including white matter 
volume reduction (Aylward et al. 1995; Di Sclafani et al. 1997; Jernigan et al. 2005; Stout et 
al. 1998), white matter signal abnormalities (Archibald et al. 2004), caudate atrophy (Paul et 
al. 2002; Stout et al. 1998), and cortical thinning (Thompson et al. 2005) were frequently 
observed in late stage human immunodeficiency virus (HIV) infection. Since the advent of 
cART, there has been a dramatic reduction in the incidence of dementia (Ances and Ellis 
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2007; McArthur et al. 2004) though the number of patients experiencing mild to moderate 
cognitive dysfunction may be on the rise (McArthur et al. 2003; McCutchan et al. 2007; 
Sacktor et al. 2002). Findings such as these have led researchers to postulate that the central 
nervous system (CNS) acts as a protected reservoir for HIV infection in the setting of cART 
(Anthony and Bell 2008; Hult et al. 2008), and despite adequate improvements in systemic 
immune function and viral suppression, the brain remains vulnerable to HIV-associated 
injury.
To date, there have been a limited number of studies directly examining the effects of HIV 
on the CNS in the context of cART. Early studies by the HIV Neuroimaging Consortium 
(HIVNC) and others using magnetic resonance spectroscopy (MRS) have demonstrated 
regional metabolite changes indicating increased inflammation and neuronal injury, 
especially in the frontal white matter and subcortical nuclei (Chang et al. 2004; Sacktor et al. 
2005; Yiannoutsos et al. 2004; Harezlak et al. 2011). Several studies have also successfully 
used diffusion tensor imaging (DTI) to demonstrate general, regional, and tract specific 
reduction of fractional anisotropy in white matter areas of HIV patients (Chen et al. 2009; 
Pfefferbaum et al. 2007, 2009; Ragin et al. 2004; Tate et al. 2010; Wu et al. 2006). 
Combined, these findings suggest that HIV infection is deleterious to brain white matter, 
though there have been very few studies directly examining white matter atrophy, 
particularly in the context of stable HIV disease and cART.
To address this gap in the literature, the present study examined the structural morphometry 
of the midsagittal corpus callosum (CC; a large prominent white matter structure) among 
HIV-infected patients on cART enrolled in the HIVNC, a large multi-center prospective 
study designed to assess the effects of chronic HIV disease and treatment on CNS function. 
We also examined the relationship between CC morphometry and various host and disease-
related factors to identify relationships between these measures.
Methods
Participants
Structural MRI and clinical data from 216 HIV-infected participants (181 M; 35 F) enrolled 
in the multisite HIVNC study were examined. Potential subjects were recruited by nurse or 
physician referral from outpatient HIV/AIDS clinics affiliated with the Consortium. Each 
potential participant underwent a screening interview administered by trained nurses to 
identify eligibility. All eligible study patients were informed to the nature and scope of the 
study and were required to provide signed consent. All recruitment and data management 
procedures were performed in accordance with IRB-approved protocols.
Inclusion criteria were as follows: Patients were required to have a nadir CD4 count <200 
cells/mm3, on stable antiretroviral regimen with any FDA-approved antiretroviral therapy 
(i.e., nucleoside, non-nucleoside, and/or protease inhibitors) for at least 12 consecutive 
weeks prior to study screening, hemoglobin >9.0 gm/dl, serum creatinine ≤3× upper limits 
of normal (ULN), and AST (SGOT), ALT (SGPT), and alkaline phosphatase ≤3× ULN. 
Exclusion criteria included severe premorbid or comorbid psychiatric disorders 
(schizophrenia, bipolar disorder, and active depression), confounding neurologic disorders 
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(chronic seizures, stroke, head trauma resulting in loss of consciousness >30 min, multiple 
sclerosis), brain infection (e.g., fungal meningitis, toxoplasmosis, progressive multifocal 
leukoencephalopathy, or neoplasms), active alcohol and drug abuse or related medical 
complications within 6 months of study, and diabetes mellitus with a fasting glucose >140 
mg/dl.
In a post hoc attempt to enrich the sample, we also examined all the available structural MRI 
data of 139 control participants (67 M; 72 F) from a previously published study (Bigler et al. 
1996, 1999) for a limited number of statistical procedures. Exclusion criteria for the control 
participants were as follows: diagnostic history of severe psychiatric disorders 
(schizophrenia, bipolar, or major depression), history of neurologic disorder (epilepsy, 
stroke, head injury with loss of consciousness >5 min), and/or alcohol or drug abuse history. 
Additional demographic data for HIV and control participants are displayed in Table 1.
Clinical measures
CD4 cell count and HIV RNA plasma concentrations were obtained from each of the HIV-
infected patients within 4 weeks of MRI examination using standardized methods (i.e., 
Roche Amplicor techniques). Each patient’s nadir CD4 count (lowest lymphocyte count) 
was also acquired from the patient’s medical history. Additionally, we quantified duration of 
HIV infection by subtracting the diagnosis date from the date of the image acquisition. This 
resulted in a length of disease variable quantified in years and months. For a subset of HIV-
infected patients (N=86), cerebral spinal fluid (CSF) RNA concentrations were also 
available and examined.
Neurocognitive status was assessed using the AIDS Dementia Complex (ADC) scale as 
previously described (Price et al. 1988). Patients were assessed on both clinical and 
neuropsychological tests and rated as having no impairment, stage 0; subclinical 
impairment, 0.5; mild impairment, stage 1; moderate, stage 2; or severe, stage 3. 
Neuropsychological impairment was defined as performance of at least 1.0 standard 
deviation below normative values on two or more neuropsychological tests or at least 2.0 
standard deviations below normative values on one or more tests that included measures of 
attention, executive function, working memory, learning/memory, and psycho-motor speed. 
Subsequent to the inception of this study, Antinori and colleagues published a new 
classification in which ADC stage 0.5 (neuropsychological impairment without functional 
disturbances) would correspond to asymptomatic neurocognitive impairment, ADC stage 1 
would correspond to mild neurocognitive disorder, and ADC stage 2 or greater would 
correspond to HIV-associated dementia (Antinori et al. 2007). For the purpose of group 
comparison, we combined patients with ADC stages 0 and 0.5 into an asymptomatic group 
(N=181) and patients with ADC stages ≥1 into a symptomatic group (N= 35). Of the 86 
patients with CSF RNA measures, 24 participants had detectable CSF RNA (~28%), and 17 
were classified as having ADC stage ≥1 (~20%).
Neuroimaging
Imaging data used in the current analyses were available from seven sites from across the 
USA, all of which used GE Signa 1.5-T scanners (GE Medical Systems, Milwaukee, WI, 
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USA) with similar operating systems and standard GE quadrature head coils. The consistent 
utilization of prescribed imaging parameters and the quality of the imaging data were 
assessed using automated header checking programs and manual inspection (e.g., for 
artifact, complete anatomical coverage, etc.). The whole head T1-weighted spoiled gradient-
echo volumetric (repetition time/echo time (TR/TE)=16/600; field of view (FOV)=20 cm; 
slice thickness=1.3 mm; matrix size=256×128, with 1 NEX) images were analyzed in this 
study.
For the group comparison analyses, we quantified the CC utilizing the same methods in a 
cohort of healthy controls from a large imaging study with compatible acquisition 
parameters (Bigler et al. 1999). Data for this comparison cohort were obtained using a GE 
1.5-T scanner with similar resolution in the sagittal plane utilizing the following scan 
parameters: TR/TE=15/500, FOV=24 cm, slice thickness= 2 mm, and matrix size=256×256, 
with 1 NEX.
Morphometric analyses
For each HIV-infected and control participant, the midsagittal slice of the CC was selected 
and manually traced by several trained raters, who were unaware of subject’s diagnosis, 
using the publicly available software 3D Slicer (SPL, Brigham and Women’s Hospital, 
Boston, MA, USA). The midsagittal slice was identified using the falx cerebri and cerebral 
aqueduct as anatomical landmarks, as well as 3D Slicer’s view of the horizontal plane for 
visual confirmation in accordance with established protocols (Denenberg et al. 1991). 
Methods of CC delineation are visually represented and further explained in Fig. 1. Intra- 
and inter-rater reliability for manual tracing was periodically examined throughout the study 
and found to be greater than or equal to 0.99 (intraclass correlation coefficient) suggesting 
highly reproducible results.
Once manually traced, the label map was then subjected to two automated procedures 
designed to divide the CC into five standardized areas and quantify the linear width along 
the craniocaudal extent of the CC. The CC was first divided into five standardized areas 
using a modified Witeleson protocol (Kochunov et al. 2005; Witelson 1989). This protocol 
uses standardized divisions of the linear length of the CC after rotating the CC such that the 
long axis of the CC is parallel to the horizon as illustrated in Fig. 1. The actual areas in 
square millimeters for each segment of the CC were calculated by summing the number of 
pixels contained within the defined sub-regions and multiplying by pixel size.
In addition, the width of the CC was measured at 100 equidistant points along the length of 
the CC. This approach yields a much more detailed morphometric profile, which is 
particularly important in the context of diseases with subtle CNS effects. For this study, we 
used a conformal mapping technique developed by our laboratory (Center for Neurological 
Imaging, Brigham and Women’s Hospital) and implemented in Matlab® (Sampat et al. 
2009; Sander et al. 2008). Briefly, this method consisted of two steps. First, the pixelated 
boundary from the manual tracing is smoothed. Second, the complex geometric plane of the 
smoothed tracing is conformally mapped to a more simple geometric polygon where the 
widths can be measured at 100 equidistant points along the CC midline (for a more detailed 
description of the method, the reader is referred to Sampat et al. 2009; also see Fig. 1).
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Head size correction
Semi-automated segmentation was used to derive total intracranial volume (TICV) for each 
participant (Bigler et al. 1999; Dale et al. 1999). TICV was used to correct the CC area and 
linear widths using the following equation so that direct comparison of the measures could 
be made between individuals with largely varying head sizes (e.g., males and females):
Statistics
Differences in CC morphometry (areas and linear widths) measures between healthy HIV 
negative controls and HIV-infected patients were tested for differences using ANCOVA 
controlling for age. The relationship between the CC areas and clinical covariates for the 
HIV-infected patients was examined using linear regression models with current CD4, nadir 
CD4, plasma RNA (a binary variable representing detectable or undetectable RNA levels), 
duration of HIV infection, age, and ADC stage as candidate predictors. Variable selection 
for the regression models was performed using the Akaike information criterion (AIC) to 
choose only the important predictive factors of the CC areas. This method is preferred here 
to obtain a parsimonious model of the relationship between the candidate covariates (Cohen 
et al. 2010a) and the outcomes. In the CC linear width analyses, all candidate predictors 
were used in the linear regression models, and a smoothing method adjusting for multiple 
comparisons was utilized to obtain both the regression coefficients and their associated 
confidence bands (Laird et al. 1992). In a subsample of patients (N=86), the relationship 
between both the area and linear width analyses and CSF RNA was also examined. All 
statistical analyses were conducted in R-2.9.2 (R Development Core Team 2011).
Results
Demographic variable comparisons
There were significant differences between the three experimental groups (control, 
asymptomatic, and symptomatic) for age (p=0.0008) and between asymptomatic and 
symptomatic patients for duration of illness (p=0.002) with the symptomatic patients having 
longer average duration of illness. The asymptomatic and symptomatic groups were 
statistically similar for measures of disease severity and immunological function as 
measured by CD4 cell count (nadir and baseline), detectable plasma RNA, and CSF RNA 
(Table 1). To control for the effects of age and duration of illness, statistical analyses for 
group comparisons were made with these variables as covariates.
CC area group comparisons
Symptomatic HIV-positive subjects (ADC stage ≥1) showed reductions in all five CC areas 
when compared with healthy controls. No significant differences were found in any the CC 
areas between asymptomatic subjects (ADC stage 0) and subjects with subclinical 
impairment (ADC stage 0.5). Therefore, these groups were combined into an asymptomatic 
group for further analyses. This asymptomatic group differed from control participants for 
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all the area measures except the isthmus (p=0.20), while the differences for genu were only 
marginally significant (p=0.05). Furthermore, the genu (p= 0.04) and the isthmus (p=0.03) 
were significantly smaller in the symptomatic group compared with the asymptomatic group 
(Table 2).
CC linear width group comparisons
Regardless of linear width position examined, both HIV-infected groups displayed 
significantly smaller linear widths on average compared with control participants (Fig. 2). 
The symptomatic group demonstrated significant reductions in width in the genu (line 
segments 6–22) as well as marginally significant differences in the anterior midbody (line 
segments 25–33) compared with the asymptomatic group. In contrast, significant differences 
between the two HIV-infected groups were not found in the line segments corresponding to 
the posterior midbody, isthmus, or splenium. Combined these findings show that the linear 
widths for the asymptomatic group generally fell between those measured for the other two 
groups, consistent with a dose effect (Fig. 2).
Determinants of area measures
Multivariable linear regression models with variable selection done by AIC were used to 
determine the predictive association between each area measure and six clinical measures of 
interest. ADC stage was modestly associated with the genu (p=0.047) and the isthmus 
(p=0.027) while nadir CD4 cell count was associated with the posterior midbody (p=0.026). 
In the subsample of patients with detectable CSF RNA, no significant associations were 
found between the candidate predictors and the CC areas.
Determinants of linear width
Plots of the beta coefficients and confidence intervals for each regression result are shown in 
Fig. 3. From these plots, it is clear that the regression results were not significant for current 
CD4, presence of plasma RNA, HIV duration, and age regardless of linear width examined. 
In contrast, a lower CD4 cell count was significantly associated with shorter line segments 
corresponding to the genu (line segments 12–19), isthmus (line segments 59–66), and 
splenium (line segments 84–88). In addition, segments corresponding to the genu of the 
corpus callosum (line segments 7–18) were significantly shorter in patients with higher 
ADC stage. Again, in the subsample of patients with CSF RNA measurements, none of the 
considered predictors was significantly associated with the linear widths examined (plot not 
shown).
Discussion
This study examined structural abnormalities in the mid-sagittal CC in a large cohort of 
HIV-infected patients with history of chronic disease on stable combination therapies. The 
results demonstrate several important findings, the most significant of which is a reduction 
in area and width in HIV-infected patients compared with controls. Specifically, both 
asymptomatic and symptomatic HIV-infected groups showed significant atrophy relative to 
controls regardless of area or linear width examined. In addition, differences were found 
between the HIV-infected groups in the genu (area and linear widths), anterior midbody 
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(linear widths), and isthmus (area) with symptomatic subjects demonstrating the greatest 
degree of atrophy. These results suggest that despite treatment, there is significant and 
quantifiable CNS injury associated with HIV infection in the setting of chronic yet treated 
infection regardless of symptom presentation. Further, the strong association with nadir CD4 
count suggests that this complication may evolve during the early stages of HIV infection in 
response to progressive immune suppression and may be irreversible despite subsequent 
exposure to effective antiretroviral therapies.
These findings are based on a large sample (N=216) of chronically infected subjects with a 
history of advanced disease (mean nadir CD4=27.5 cells/mm3) but who have since shown 
significant immune reconstitution in response to treatment (mean baseline CD4=269.1 
cells/mm3; see Table 1). To our knowledge, this is the largest study of the CC in treated HIV 
subjects and extends findings from previous studies demonstrating significant reductions in 
total CC area between controls and more clinically advanced HIV-infected subjects or in 
subjects with additional comorbid risk factors such as drug and alcohol abuse (Cardenas et 
al. 2009; Chiang et al. 2007; Pfefferbaum et al. 2006; Thompson et al. 2005, 2006; 
Wohlschlaeger et al. 2009). A novel feature to our study was the utilization of 100 
equidistant linear widths in addition to five regional divisions as previously described 
(Thompson et al. 2006). Results of area analyses clearly demonstrate significant regional 
thinning across a wide range of neurologically symptomatic and asymptomatic subjects with 
greater decreases occurring in subjects with more cognitive impairment. Group differences 
were further illustrated in the analysis of the linear widths, which demonstrated a similar 
dose response to the area measures, particularly in the anterior segments.
Although the basis for these findings is not entirely understood, these measures likely reflect 
underlying structural changes in the CC. One recent pathological study (Wohlschlaeger et al. 
2009) found a significant decrease in CC area (~8%) in HIV-infected patients compared 
with controls that was associated with a global reduction in the absolute number of nerve 
fibers (~12%), with the most atrophy and reduction of nerve fibers occurring in the frontal 
and occipital regions of the CC (~28% in the anterior midbody and ~13% in the splenium). 
Moreover, the authors demonstrated alterations in the shape and caliber of axons that are 
also reflected in gross morphologic measures. In addition, there is an emerging body of 
literature based on DTI that demonstrates white matter tract changes in associated with HIV 
infection (Pfefferbaum et al. 2002, 2007, 2009; Ragin et al. 2004, 2005; Sullivan and 
Pfefferbaum 2003; Tate et al. 2010; Wu et al. 2006). Alterations in the diffusion signal and 
tractography have been observed in several areas of the brain, including the CC suggesting 
disorganization of the micro- and macro-structure of the white matter (Chiang et al. 2007). 
Thus, quantification of the midsagittal CC may provide an effective and sensitive approach 
to monitoring pathological changes in the white matter in HIV-infected patients, especially 
given the fact that the measurement error for the CC was less than 1% as shown in this 
study.
The current study shows several areas of atrophy across the length of the CC and suggests 
that in the era of cART many areas of the brain may be vulnerable to the effects of HIV, 
particularly in those subjects who have experienced severe immunological suppression. This 
is consistent with recent studies that have shown greater involvement of cortical regions, 
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including reductions in volumes of the frontal and parietal region (Cohen et al. 2010b). The 
significant relationship between ADC stage and CC thinning, particularly in anterior third or 
genu of the CC, suggests that increased frontal involvement may contribute to worsening 
symptomology. More recently, we have shown that metabolic injury of the basal ganglia and 
frontal white matter as measured by MRS was modestly predictive of ADC, consistent with 
previous immunopathological studies (Rostasy et al. 1999). Whether the addition of CC 
measurements to these indices would improve diagnostic accuracy and thereby provide a 
useful diagnostic biomarker for ADC will need to be determined in future studies.
There have been few studies describing host or viral factors that may contribute to varying 
patterns of HIV-associated brain injury in the context of chronic disease and treatment. One 
important aim of this study therefore was to examine whether factors such as CD4 cell count 
and/or plasma HIV RNA levels exerted an effect on CC morphology. We also included age 
and duration of infection as covariates to test the hypothesis that aging and chronicity of 
infection may also contribute to thinning of the CC. To our surprise, other than the expected 
associations with ADC stage, a significant predictive relationship was only found for nadir 
CD4+ cell count while no significant effect was found for age, duration of HIV infection, 
plasma, or CSF HIV RNA levels. This finding stands in contrast to study by Thompson et al. 
(2006) who showed significant associations with the baseline CD4 value. However, the 
sample size was substantially smaller in that study (N=30), and the nadir CD4 count was not 
included in the analysis.
To our knowledge, this is the first study of a large cohort of HIV-infected subjects to 
demonstrate a significant relationship between nadir CD4 and in vivo morphologic measures 
of the white matter. It also extends recent reports that demonstrated a predictive association 
between nadir CD4 cell count and cognitive impairment (Cysique et al. 2010; Munoz-
Moreno et al. 2008; Robertson et al. 2007; Valcour et al. 2006) as well as reduced cortical 
volumes in a smaller sample from the HIVNC cohort (Cohen et al. 2010b). The results of 
this study suggest that despite reconstitution of the immune system in response to cART, the 
extent of immune compromise experienced before the start of treatment may be an important 
factor leading to significant white matter atrophy. This finding also raises a larger question 
about when to initiate therapy in patients who have yet to experience an AIDS defining 
event. Accumulating evidence suggests that early initiation of treatment (CD4 cell count 
≥350 cells/mm3) is associated with improved outcomes (Emery et al. 2008). Further, data 
from the When to Start Consortium (18 cohort studies, ~45,000 patients) demonstrated that 
patients who deferred treatment until CD4 cell count fell between 251 and 350 cells/mm3 
were at increased risk for the development of AIDS and experienced higher mortality rates 
compared with those initiating therapy earlier (351 to 450 cells/mm3; Sterne et al. 2009). 
Even in the context of treatment, HIV-infected patients with lower nadir CD4 cell count do 
not experience the same degree of immune reconstitution when compared with patients with 
higher nadir CD4 cell counts (D’Amico et al. 2005). The results from the current study 
provide further support for early intervention although additional studies will be needed to 
determine the extent to which such treatment prevents or ameliorates CNS injury.
It is interesting to note that although there were significant group differences in the CC areas 
and linear widths, several asymptomatic subjects demonstrated moderate to marked atrophy 
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qualitatively similar to that observed in the overall symptomatic group (Fig. 4). 
Distinguishing clinical features, which would suggest why so much atrophy would occur in 
some of the asymptomatic subjects but not others, are not apparent from the current analysis 
although, as mentioned above, a history of advanced immunosuppression as reflected by a 
low nadir CD4 count may be one contributing factor. Importantly, these observations 
suggest that subgroups of HIV-infected patients on treatment are experiencing significant 
atrophy despite the absence of cognitive symptoms in the setting of relatively stable disease. 
Future prospective studies are needed to understand the dynamic relationships between 
regional changes in the CC and the onset of cognitive impairment in treated patients.
There are potentially several limitations to this study. One is the use of archival control data 
collected as part of another study. Although significant attempts were made to choose a 
control dataset that had similar acquisition parameters, significant demographic or other 
features could have limited the comparisons of these groups. Age and education were two 
areas shown to be different but notably the HIV-infected groups, including asymptomatic 
individuals, showed a higher percentage with greater than a high school education (53–72%) 
compared with controls (44%), suggesting higher education did not confer a protective 
effect. In addition, several statistical measures were undertaken to limit the effects of such 
demographic variables. Second, the cross-sectional design of the study limits the predictive 
assessment of the effects of various clinical, cognitive, and morphometric relationships that 
will need to be addressed in future prospective studies.
It is well established that the CC represents a major communication pathway between the 
hemispheres that is responsible for the functional integration of complex motor, cognitive, 
and behavioral tasks. As such, quantification of the CC may provide a robust approach to 
assess the functional integrity of the cerebral hemispheres among HIV-infected patients. We 
employed a novel method of CC measurement that allows for greater sensitivity when 
examining the relationship between clinical measures and morphology and potentially in 
detecting longitudinal changes. Further, the linear width measurement provided additional 
sensitivity as this approach identified additional segments (genu and splenium) that were not 
detected in the area analysis. We also show that in the context of a large multi-center study, 
it is possible to acquire reliable CC measurements. In fact, intra- and inter-rater reliability 
measures (Cronbach’s alpha >0.99) demonstrated a high degree of agreement. Combined 
these findings suggest that these methods may complement each other to provide a useful 
and robust in vivo approach to examine the progression of subtle and focal changes in the 
white matter of HIV-infected patients and their effects on cognitive function in the setting of 
chronic disease and treatment.
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Fig. 1. 
Illustration of quantification method. The left side panels show the modified Witelson 
protocol where the CC is divided into five functionally related areas. The right side of the 
figure shows the linear widths measurement method developed by our lab to quantify the 
width of the CC at 100 equidistant points along the length of the CC. First step for each 
method (see A) is to manually trace the midsagittal CC. In step B, the CC is divided into 
different area based on a standard division of the linear length. In step C, the CC is labeled 
and quantified. In step D, the manual tracing is subjected to a smoothing algorithm and the 
median curve of the CC is produced (black line). In step E, the median curve is divided into 
100 equal points where the line is then bisected to produce a linear width at that point
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Fig. 2. 
Comparison of the line widths between the groups. a The actual beta (black line; x-axis) and 
the 95% confidence interval (blue dashed line) when comparing the ADC patients and 
controls. b The actual beta (black line) and the 95% confidence interval (blue dashed line) 
when comparing the NA patients and controls. c The actual beta (black line) and the 95% 
confidence interval (blue dashed line) when comparing the ADC and NA patients. d The 
actual linear width differences along the whole length of the CC for each of the groups 
(controls = black line, NA = red dashed line, and ADC = green dashed line)
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Fig. 3. 
Figure illustrating the beta values (black line; x-axis) and the 95% confidence interval (blue 
dashed lines) for each multivariable regression analysis
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Fig. 4. 
Figure illustrating readily observable qualitative difference across controls and patients with 
similar demographic and clinical variables. ADC ADC staging, Nadir Nadir CD4 cell count, 
PVL plasma viral load (all patients were less than 75), CCD4 current CD4 cell count
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Table 1
Descriptive statistics for major demographic variables
ADC Stage Total HIV Controls
0 and 0.5 ≥1
N 181 35 216 139
Gender (% male) 82 89 88 48
Age (years) 46.7±8.3a 52.2±8.5 47.6±8.6 37.0±13.6
Ethnicity (% Caucasian) 69 74 69 85
Education level (% high school or less) 39 31 38 23
% IV drug use 20 40 23 Not available
Duration of infection (years) 11.5±6.6 15.0±5.7 12.0±6.6 Not applicable
CD4 count (log10 cells/ml) 2.42±0.36 2.46±0.34 2.43±0.35 Not applicable
Nadir CD4 (log10 cells/ml) 1.44±0.58 1.46±0.61 1.44±0.58 Not applicable
% Undetectable plasma RNA viral load 75 86 76 Not applicable
% known on ART at baseline (uninterrupted) 92 94 93 Not applicable
a
The numbers after ± are standard deviations
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Table 2
The area difference and actual p value are shown for comparison between the three groups separately adjusted 
for age and gender (significant comparisons are bolded)
Area measure NA vs controls ADC vs controls ADC vs NA
Genu −11.34 (0.048) −28.35 (0.002) −18.58 (0.042)
Anterior midbody −4.78 (0.015) −9.52 (0.002) −5.01 (0.090)
Posterior midbody −4.57 (0.013) −8.05 (0.006) −3.62 (0.170)
Isthmus −2.45 (0.204) −8.36 (0.006) −5.93 (0.025)
Splenium −10.50 (0.009) −18.09 (0.004) −8.03 (0.182)
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